News

New findings resulting from a research collaboration between miRagen Therapeutics Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, and Yale University scientists demonstrate that synthetic microRNA-29 Mimic promiR-29 reversed fibrosis in a mouse model of pulmonary fibrosis. These findings were published in the journal EMBO Molecular Medicine…

Inflammation has long been considered an integral element of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis, one of a broad category of lung diseases classified as Interstitial lung disease (ILD) that includes more than 130 disorders characterized by scarring (i.e. fibrosis) and/or inflammation…

Researchers at Brown University in Providence, Rhode Island and collaborating institutions report having achieved some progress in the battle against idiopathic pulmonary fibrosis (IPF), a devastating lung disease that afflicts millions of people worldwide. Two experimental drugs have recently showed promise in clinical trials, and now a study last…

Founded in 2000, the Pulmonary Fibrosis Foundation (PFF) is a nonprofit organization dedicated to supporting research on the treatment of pulmonary fibrosis (PF) and finding a cure for the disease, as well as assisting patients and their families. The organization engages with local and regional PF communities all over the…

The Pulmonary Fibrosis Foundation (PFF) recently submitted research data about more than 1,100 patients who suffer from pulmonary fibrosis (PF) to the U.S. Food and Drug Administration (FDA), in order to participate in the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis. The meeting will take place on September…

Half of it has already passed, but the 2014 Pulmonary Fibrosis Awareness Month in September continues forward, full of activities. Having been established by the Coalition for Pulmonary Fibrosis (CPF), this is the 12th year that the organization is using the month to raise awareness for…

  Pharmaceutical company Boehringer Ingelheim Pharmaceuticals, Inc. is sponsoring the documentary Every Breath Counts: Idiopathic Pulmonary Fibrosis, which will air on the Discovery Channel on September 13th and 27th at 8:00 am ET/PT, and can also be viewed at www.everybreathcountsfilm.com. The documentary was created in collaboration with the Pulmonary…

Cases of idiopathic pulmonary fibrosis (IPF) may be caused by exposure to asbestos, as suggested by a recent study conducted at Imperial College London in the United Kingdom, and presented at the European Respiratory Society’s conference. The new mortality data about IPF, asbestosis, and mesothelioma may offer new information for how to…

The clinical stage specialty pharmaceutical company Pacific Therapeutics announced that is looking for a commercialization partner for the sale of PTL-202, as a result of positive results of recent pre-clinical studies and an initial phase I clinical trial of its lead drug candidate for pulmonary fibrosis. PTL-202 is a combination of…

Pacific Therapeutics Ltd., a pharmaceutical company focused on the reformulation of existing approved drugs, recently announced the end of an initial phase 1 trial of its drug candidate for Idiopathic Pulmonary Fibrosis, PTL-202, combined with an important antioxidant amino acid, with positive signs on its effectiveness, low side effects,…